Should breast screening depend on risk instead of age?

Breast cancer screening is becoming more personalized. A new randomized trial from the WISDOM study found that a risk-based approach, which used age, family history, breast density, genetic testing, and other factors to set screening intensity, was noninferior to the trial’s annual-screening strategy for detecting more advanced cancers.

That does not mean U.S. screening guidance has changed broadly. For now, the CDC and the U.S. Preventive Services Task Force still recommend routine mammography mainly by age for average-risk women, with more individualized decisions for people at higher risk.

What risk-based screening means

In plain language, risk-based screening tries to match the test schedule to a person’s chance of developing breast cancer. Someone at lower risk might need less frequent screening, while someone at higher risk might be screened more often or offered MRI and risk-reduction counseling.

The appeal is straightforward: give more screening to people who are more likely to benefit, and spare some lower-risk people from unnecessary tests. In theory, that could also reduce false alarms, extra biopsies, and costs. In practice, it is more complicated.

What the WISDOM trial tested

The WISDOM trial, published in JAMA, was a large pragmatic randomized study of women ages 40 to 74 in all 50 states. One group received annual mammography. The other received screening recommendations based on a risk assessment that included sequencing of susceptibility genes, a polygenic risk score, the Breast Cancer Surveillance Consortium model, and other factors.

The trial’s main question was whether the risk-based strategy was at least as safe as annual screening for detecting stage IIb or later cancers. It found that the risk-based approach met that noninferiority goal. The study also found fewer mammograms in the risk-based group, but it did not lower biopsy rates overall.

What the study did not prove

Experts are still cautious for several reasons. First, the trial compared one structured screening strategy with another, not risk-based screening against no screening. Second, the average follow-up was a little over five years, which may be too short to show long-term effects on breast cancer deaths. Third, most participants were non-Hispanic White, so it is not yet clear how well the approach works across all U.S. populations.

That matters because the best screening plan may depend on whether someone has dense breasts, a strong family history, a known high-risk gene, prior chest radiation, or a previous breast lesion. The evidence is still evolving for some of these groups.

How current U.S. guidance compares

The CDC says mammograms are the best way for many women to find breast cancer early, and it notes that the USPSTF recommends mammography every two years for women ages 40 to 74 at average risk. The USPSTF also says evidence is insufficient to judge supplemental ultrasound or MRI for women with dense breasts who have an otherwise negative mammogram.

In other words, current U.S. guidance still centers on age-based routine screening for average-risk adults, not a universal risk-score model. Risk-based screening is promising, but it is not yet the standard default for most people.

Who may benefit most from a more personalized approach

A personalized approach may be most useful for people whose risk is clearly above or below average, including those with a strong family history, known inherited mutations, dense breasts, or prior high-risk biopsy findings. For those patients, a clinician may reasonably discuss whether earlier, more frequent, or supplemental screening makes sense.

People at average risk, however, should not assume they need to switch away from guideline-based screening on their own. The current evidence supports discussion, not self-directed changes.

What readers can do now

If you are due for screening, the most practical next step is to ask your clinician which breast cancer screening schedule fits your risk profile and how often you should be screened. If you know you have dense breasts, a strong family history, or a known genetic risk, bring that up directly.

If you already have a routine screening plan, this new research is best viewed as a sign that breast cancer screening may become more personalized over time, not as a reason to stop or start screening without medical guidance.

The bottom line: risk-based breast screening looks feasible and may eventually help refine who gets what type of screening. For now, though, standard U.S. guideline-based mammography remains the default for most average-risk women.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.